Drug Profile
Research programme: peanut allergy immunotherapy - Perosphere
Alternative Names: PER1080Latest Information Update: 22 Jan 2019
Price :
$50
*
At a glance
- Originator Perosphere
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 17 Jan 2019 Perosphere has been acquired by AMAG Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for research development in Peanut-hypersensitivity in USA (Parenteral)
- 17 Apr 2013 Early research is ongoing in USA